PerpEquities

Equity · Healthcare

Gilead Sciences, Inc. (GILD) perpetual futures

GILD perpetual futures on 7 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade GILDUSDT.

Gilead Sciences is a global biopharmaceutical company that develops and commercializes innovative therapies for HIV/AIDS, COVID-19, liver diseases, cancers, and other serious conditions.

$146.11+1.9%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · BingX (GILD-USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

7/7 live markets
Venues
7
Live markets
7/7
24h volume
$573.7KCoverage: 6/7 marketsExchange-reported volume: $1.8M
Open interest
$158.7KCoverage: 5/7 markets
Best liquidity
$488.9K
LBank
Tightest spread
+13.7 bps
LBank
Highest volume
$405K
HTX
Settlement mix
USDT · 6/7
Perp/spot vol.
0.00x
Spot volume $718.8M
OI / float
0.00%
Float $181B
Spot performance
1D+1.87%
5D+0.65%
1M+5.82%
6M+0.98%
YTD+19.28%
1Y+30.10%

Venue matrix

7 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeGILD-USDTTrading$146.20+5.5% APR
+0.00500% every 8h
+19.8 bps$2.6K$1.2M$1.3KUSDT-
HTXTradeGILD/USDTTrading$146.360.0% APR
0.000% every 8h
+426.3 bps$0$405K$4.9KUSDT-
Helix (Injective)TradeGILD/USDCTrading$146.79+3.6% APR
+0.00042% every 1h
--$85K-USDC12x
BybitTradeGILD/USDTTrading$146.360.0% APR
0.000% every 8h
+13.7 bps$2.1K$40.8K$64.3KUSDT25x
BitgetTradeGILD/USDTTrading$145.920.0% APR
0.000% every 8h
+18.5 bps$470.2K$38.1K$80.9KUSDT20x
Gate.ioTradeGILD/USDTTrading$146.610.0% APR
0.000% every 8h
+111.8 bps$15.7K$4.4K$7.3KUSDT20x
LBankTradeGILD/USDTTrading$146.110.0% APR
0.000% every 8h
+13.7 bps$488.9K$500.1-USDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Thin liquidity · 2 of 7 venues absorb $10k · Typical cost: +27.1 bps – +49.2 bps

Cheapest execution: Bitget · +16.1 bps

Too thin: BingX, Bybit

No fresh book data: Gate.io, HTX, Helix (Injective)

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

GILD

Tightest spread

GILD

Highest volume

GILD

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 4h ago
Market cap
$181.8B
Updated 4h ago
Revenue
$30.5B
Trailing 12 months
Revenue growth
+4%
Next fiscal year
Profit margin
-10.6%
P/E
-56.3
Peer P/E 22.3
Free cash flow
$13.2B
Trailing 12 months
More metrics
Net income
-$3.2B
Trailing 12 months
P/S
6.0
Peer P/E
22.3
Similar listed perps
Revenue estimate
$30.7B
Next fiscal year
Earnings
2026-10-29
Revenue est. $7.8B · Updated 4h ago
Dividend
$0.82
2026-09-15

Fundamental detail

Annual + quarterly
Latest revenue$29.4B
Net margin+28.9%
Free cash flow$9.5B
Net debt$17.4B
2020$24.7B
2021$27.3B
2022$27.3B
2023$27.1B
2024$28.8B
2025$29.4B
PeriodRevenueGrowthNet incomeFCF
2020$24.7B+10%$123M$7.5B
2021$27.3B+11%$6.2B$10.8B
2022$27.3B0%$4.6B$8.3B
2023$27.1B-1%$5.7B$7.4B
2024$28.8B+6%$480M$10.3B
2025$29.4B+2%$8.5B$9.5B
PeriodGross marginOperating marginNet marginROEROA
2020+81.5%+16.5%+0.5%+0.7%+0.2%
2021+75.8%+36.3%+22.8%+29.5%+9.2%
2022+79.3%+26.9%+16.8%+21.6%+7.3%
2023+76.0%+28.0%+20.9%+24.8%+9.1%
2024+78.3%+5.8%+1.7%+2.5%+0.8%
2025+78.8%+39.7%+28.9%+37.5%+14.4%
PeriodCashDebtNet debtCurrent ratio
2020$6B$31.4B$25.4B1.40
2021$5.3B$26.7B$21.4B1.27
2022$5.4B$25.2B$19.8B1.29
2023$6.1B$25B$18.9B1.43
2024$10B$26.7B$16.7B1.60
2025$7.6B$24.9B$17.4B1.55
PeriodMarket capEnterprise valueP/SP/E
2020$73.2B$98.6B3.0595.1
2021$91.2B$112.6B3.314.6
2022$107.7B$127.6B3.923.5
2023$101.1B$120B3.717.8
2024$115.2B$131.9B4.0243.1
2025$152.7B$170.1B5.217.9
Q3 2024$7.5B
Q4 2024$7.6B
Q1 2025$6.7B
Q2 2025$7.1B
Q3 2025$7.8B
Q4 2025$7.9B
Q1 2026$7B
Q2 2026$7.8B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$7.5B+7%$1.3B$4.2B
Q4 2024$7.6B+6%$1.8B$2.8B
Q1 2025$6.7B0%$1.3B$1.7B
Q2 2025$7.1B+2%$2B$720M
Q3 2025$7.8B+3%$3.1B$4B
Q4 2025$7.9B+5%$2.2B$3.1B
Q1 2026$7B+4%$2B$2.4B
Q2 2026$7.8B+10%-$10.5B$3.7B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+79.1%+11.8%+16.6%+6.8%+2.3%
Q4 2024+79.1%+32.4%+23.6%+9.2%+3.0%
Q1 2025+76.9%+33.6%+19.7%+6.9%+2.3%
Q2 2025+78.8%+34.9%+27.7%+10.0%+3.5%
Q3 2025+79.8%+42.8%+39.3%+14.2%+5.2%
Q4 2025+79.5%+37.7%+27.5%+9.6%+3.7%
Q1 2026+79.2%+37.2%+29.0%+8.6%+3.6%
Q2 2026+79.8%-133.2%-134.5%-88.7%-21.3%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$5B$23.2B$18.2B1.26
Q4 2024$10B$27.3B$17.3B1.60
Q1 2025$7.9B$25B$17B1.37
Q2 2025$5.1B$24.9B$19.8B1.32
Q3 2025$7.3B$24.9B$17.6B1.45
Q4 2025$7.6B$24.9B$17.4B1.55
Q1 2026$7.6B$22.2B$14.5B1.97
Q2 2026$3.2B$26.2B$23.1B1.27
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$104.5B$122.8B13.921.0
Q4 2024$115.3B$132.6B15.216.1
Q1 2025$139.6B$156.6B20.926.4
Q2 2025$138B$157.8B19.517.7
Q3 2025$138B$155.6B17.811.3
Q4 2025$152.4B$169.8B19.217.4
Q1 2026$173.1B$187.6B24.921.4
Q2 2026$157B$180.1B20.1-3.7

Refreshed 4h ago

Charts: revenue, profit, cash flow & valuation
Revenue$7.8BQ2 2026
$2B$4B$5.9B$7.9BQ3 2023: $7.1BQ4 2023: $7.1BQ1 2024: $6.7BQ2 2024: $7BQ3 2024: $7.5BQ4 2024: $7.6BQ1 2025: $6.7BQ2 2025: $7.1BQ3 2025: $7.8BQ4 2025: $7.9BQ1 2026: $7BQ2 2026: $7.8BQ3 2023Q2 2026
Net income-$10.5BQ2 2026
-$7.1B-$3.7B-$335M$3.1BQ3 2023: $2.2BQ4 2023: $1.4BQ1 2024: -$4.2BQ2 2024: $1.6BQ3 2024: $1.3BQ4 2024: $1.8BQ1 2025: $1.3BQ2 2025: $2BQ3 2025: $3.1BQ4 2025: $2.2BQ1 2026: $2BQ2 2026: -$10.5BQ3 2023Q2 2026
EBITDA-$10BQ2 2026
-$6.4B-$2.7B$935.5M$4.6BQ3 2023: $3.2BQ4 2023: $2.6BQ1 2024: -$3.5BQ2 2024: $3BQ3 2024: $1.9BQ4 2024: $3.1BQ1 2025: $2.6BQ2 2025: $3.4BQ3 2025: $4.6BQ4 2025: $3BQ1 2026: $3BQ2 2026: -$10BQ3 2023Q2 2026
Free cash flow$3.7BQ2 2026
$1B$2.1B$3.1B$4.2BQ3 2023: $1.6BQ4 2023: $2BQ1 2024: $2.1BQ2 2024: $1.2BQ3 2024: $4.2BQ4 2024: $2.8BQ1 2025: $1.7BQ2 2025: $720MQ3 2025: $4BQ4 2025: $3.1BQ1 2026: $2.4BQ2 2026: $3.7BQ3 2023Q2 2026
EPS-$8.45Q2 2026
-$5.73-$3.01-$0.29$2.43Q3 2023: $1.73Q4 2023: $1.14Q1 2024: -$3.34Q2 2024: $1.29Q3 2024: $1Q4 2024: $1.42Q1 2025: $1.04Q2 2025: $1.56Q3 2025: $2.43Q4 2025: $1.74Q1 2026: $1.61Q2 2026: -$8.45Q3 2023Q2 2026
Cash / Debt$3.2BQ2 2026
$6.8B$13.7B$20.5B$27.3BQ3 2023 · Cash: $5.7BQ3 2023 · Debt: $25BQ4 2023 · Cash: $6.1BQ4 2023 · Debt: $25.7BQ1 2024 · Cash: $4.7BQ1 2024 · Debt: $25.2BQ2 2024 · Cash: $2.8BQ2 2024 · Debt: $23.4BQ3 2024 · Cash: $5BQ3 2024 · Debt: $23.2BQ4 2024 · Cash: $10BQ4 2024 · Debt: $27.3BQ1 2025 · Cash: $7.9BQ1 2025 · Debt: $25BQ2 2025 · Cash: $5.1BQ2 2025 · Debt: $24.9BQ3 2025 · Cash: $7.3BQ3 2025 · Debt: $24.9BQ4 2025 · Cash: $7.6BQ4 2025 · Debt: $24.9BQ1 2026 · Cash: $7.6BQ1 2026 · Debt: $22.2BQ2 2026 · Cash: $3.2BQ2 2026 · Debt: $26.2BQ3 2023Q2 2026
CashDebt
Profitability+79.8%Q2 2026
-80.9%-27.4%+26.2%+79.8%Q3 2023 · Gross margin: +77.8%Q4 2023 · Gross margin: +70.6%Q1 2024 · Gross margin: +76.8%Q2 2024 · Gross margin: +77.8%Q3 2024 · Gross margin: +79.1%Q4 2024 · Gross margin: +79.1%Q1 2025 · Gross margin: +76.9%Q2 2025 · Gross margin: +78.8%Q3 2025 · Gross margin: +79.8%Q4 2025 · Gross margin: +79.5%Q1 2026 · Gross margin: +79.2%Q2 2026 · Gross margin: +79.8%Q3 2023 · Operating margin: +37.2%Q4 2023 · Operating margin: +22.7%Q1 2024 · Operating margin: -64.6%Q2 2024 · Operating margin: +38.0%Q3 2024 · Operating margin: +11.8%Q4 2024 · Operating margin: +32.4%Q1 2025 · Operating margin: +33.6%Q2 2025 · Operating margin: +34.9%Q3 2025 · Operating margin: +42.8%Q4 2025 · Operating margin: +37.7%Q1 2026 · Operating margin: +37.2%Q2 2026 · Operating margin: -133.2%Q3 2023 · Net margin: +30.9%Q4 2023 · Net margin: +20.1%Q1 2024 · Net margin: -62.4%Q2 2024 · Net margin: +23.2%Q3 2024 · Net margin: +16.6%Q4 2024 · Net margin: +23.6%Q1 2025 · Net margin: +19.7%Q2 2025 · Net margin: +27.7%Q3 2025 · Net margin: +39.3%Q4 2025 · Net margin: +27.5%Q1 2026 · Net margin: +29.0%Q2 2026 · Net margin: -134.5%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth+10.2%Q2 2026
+2.3%+5.0%+7.6%+10.2%Q2 2024: +5.4%Q3 2024: +7.0%Q4 2024: +6.4%Q1 2025: -0.3%Q2 2025: +1.8%Q3 2025: +3.0%Q4 2025: +4.7%Q1 2026: +4.4%Q2 2026: +10.2%Q3 2023Q2 2026
Shares outstanding1.2BQ2 2026
314.8M629.5M944.3M1.3BQ3 2023: 1.3BQ4 2023: 1.3BQ1 2024: 1.2BQ2 2024: 1.3BQ3 2024: 1.3BQ4 2024: 1.3BQ1 2025: 1.3BQ2 2025: 1.3BQ3 2025: 1.3BQ4 2025: 1.3BQ1 2026: 1.3BQ2 2026: 1.2BQ3 2023Q2 2026
Valuation-3.7Q2 2026
2.510.518.526.4Q3 2023 · P/E: 10.7Q4 2023 · P/E: 17.6Q1 2024 · P/E: -5.5Q2 2024 · P/E: 13.3Q3 2024 · P/E: 21.0Q4 2024 · P/E: 16.1Q1 2025 · P/E: 26.4Q2 2025 · P/E: 17.7Q3 2025 · P/E: 11.3Q4 2025 · P/E: 17.4Q1 2026 · P/E: 21.4Q2 2026 · P/E: -3.7Q3 2023 · P/S: 13.3Q4 2023 · P/S: 14.2Q1 2024 · P/S: 13.6Q2 2024 · P/S: 12.3Q3 2024 · P/S: 13.9Q4 2024 · P/S: 15.2Q1 2025 · P/S: 20.9Q2 2025 · P/S: 19.5Q3 2025 · P/S: 17.8Q4 2025 · P/S: 19.2Q1 2026 · P/S: 24.9Q2 2026 · P/S: 20.1Q3 2023Q2 2026
P/EP/S
Revenue$29.4B2025
$7.4B$14.7B$22.1B$29.4B2018: $22.1B2019: $22.4B2020: $24.7B2021: $27.3B2022: $27.3B2023: $27.1B2024: $28.8B2025: $29.4B20182025
Net income$8.5B2025
$2.1B$4.3B$6.4B$8.5B2018: $5.5B2019: $5.4B2020: $123M2021: $6.2B2022: $4.6B2023: $5.7B2024: $480M2025: $8.5B20182025
EBITDA$13.6B2025
$3.4B$6.8B$10.2B$13.6B2018: $10.3B2019: $7.6B2020: $4.1B2021: $11.3B2022: $8.9B2023: $10.5B2024: $4.4B2025: $13.6B20182025
Free cash flow$9.5B2025
$2.7B$5.4B$8.1B$10.8B2018: $7.5B2019: $8.3B2020: $7.5B2021: $10.8B2022: $8.3B2023: $7.4B2024: $10.3B2025: $9.5B20182025
EPS$6.782025
$1.7$3.39$5.09$6.782018: $4.172019: $4.222020: $0.12021: $4.932022: $3.642023: $4.52024: $0.382025: $6.7820182025
Cash / Debt$7.6B2025
$7.9B$15.7B$23.6B$31.4B2018 · Cash: $17.9B2018 · Debt: $27.3B2019 · Cash: $11.6B2019 · Debt: $24.6B2020 · Cash: $6B2020 · Debt: $31.4B2021 · Cash: $5.3B2021 · Debt: $26.7B2022 · Cash: $5.4B2022 · Debt: $25.2B2023 · Cash: $6.1B2023 · Debt: $25B2024 · Cash: $10B2024 · Debt: $26.7B2025 · Cash: $7.6B2025 · Debt: $24.9B20182025
CashDebt
Profitability+78.8%2025
+20.4%+40.7%+61.1%+81.5%2018 · Gross margin: +78.1%2019 · Gross margin: +79.2%2020 · Gross margin: +81.5%2021 · Gross margin: +75.8%2022 · Gross margin: +79.3%2023 · Gross margin: +76.0%2024 · Gross margin: +78.3%2025 · Gross margin: +78.8%2018 · Operating margin: +37.1%2019 · Operating margin: +19.1%2020 · Operating margin: +16.5%2021 · Operating margin: +36.3%2022 · Operating margin: +26.9%2023 · Operating margin: +28.0%2024 · Operating margin: +5.8%2025 · Operating margin: +39.7%2018 · Net margin: +24.7%2019 · Net margin: +24.0%2020 · Net margin: +0.5%2021 · Net margin: +22.8%2022 · Net margin: +16.8%2023 · Net margin: +20.9%2024 · Net margin: +1.7%2025 · Net margin: +28.9%20182025
Gross marginOperating marginNet margin
Revenue growth+2.4%2025
+2.2%+5.0%+7.8%+10.6%2019: +1.5%2020: +10.0%2021: +10.6%2022: -0.1%2023: -0.6%2024: +6.0%2025: +2.4%20182025
Shares outstanding1.3B2025
327M654M981M1.3B2018: 1.3B2019: 1.3B2020: 1.3B2021: 1.3B2022: 1.3B2023: 1.3B2024: 1.3B2025: 1.3B20182025
Valuation17.92025
148.8297.5446.3595.12018 · P/E: 14.92019 · P/E: 15.32020 · P/E: 595.12021 · P/E: 14.62022 · P/E: 23.52023 · P/E: 17.82024 · P/E: 243.12025 · P/E: 17.92018 · P/S: 3.72019 · P/S: 3.72020 · P/S: 3.02021 · P/S: 3.32022 · P/S: 3.92023 · P/S: 3.72024 · P/S: 4.02025 · P/S: 5.220182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-10-29
Revenue est. $7.8B · Updated 4h ago
Dividend
$0.82
2026-09-15

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-0.44$30.7B+4%16
FY 20279.89$32.7B+11%16
FY 202810.66$34.4B+17%10
FY 202912.04$36.9B+25%4
FY 203013.09$39B+32%4
Q1 20272.30$7.4B+7%5

Company events

6
2026-10-29EarningsActual - / Estimate 2.15-
2026-09-15Dividend$0.82-
2026-08-04EarningsActual -6.75 / Estimate -7.25Beat
2026-06-15Dividend$0.82-
2026-05-07EarningsActual 2.03 / Estimate 1.91Beat
2026-03-13Dividend$0.82-

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Sep 15, 2026, 03:25 AM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Daniel O'Day
Employees
17,000
IPO date
Jan 22, 1992
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei3.5
Piotroski scorei5/9
FMP ratingiC-
Owner earningsi$3.83B$3.08 per share
ESG risk ratingiB-Industry rank: 26 out of 27

Rating factors

Return on equityi
1
Return on assetsi
1
Debt to equityi
1
Price to earningsi
1
Price to booki
1
Market cap history
$178.64B+15.7%Jun 26Sep 26
$154.38B$168.39B$182.40BHigh: $182.40B · 2026-08-24Low: $154.38B · 2026-06-15Latest: $178.64B · 2026-09-11Jun 26Jul 26Aug 26Sep 26
Latest: $178.64B · 2026-09-11High: $182.40B · 2026-08-24Low: $154.38B · 2026-06-15
Largest fund holders
FundWeightShares held
VTI0.22%39.5M
VOO0.25%32.6M
QQQ0.8%26.4M
IVV0.27%15.9M
1657.T0.21%15.9M
SPY0.27%15.2M
FXAIX0.25%14.4M
VTV0.6%11.8M
VCPA.S0.23%11M
XLV3.01%9M
FCNKX0.67%8M
VIG0.7%7M

Analyst track record

How the analysts covering GILD have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings220664
Analysts2944
Buy / hold / sell185 / 35 / 0475 / 189 / 0
Upgrades / downgrades / initiations3 / 1 / 313 / 3 / 9
Price targets hit / missed78 / 119 (40%)475 / 119 (80%)
Avg. return after a rating (TipRanks)-1.1%+56.4%
Best / worst call+52.4% / -19.6%+14,381.0% / -19.6%

After buy calls on this stock: median 21-day move +1.1% vs S&P 500 -0.5% (n = 475)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Evan SeigermanBMO Capital100% hit rate on this stock · 26 targets measuredBuytarget $174Aug 27, 2026
  2. Tyler Van BurenTD Cowen100% hit rate on this stock · 23 targets measuredBuytarget $160Aug 4, 2026
  3. Terence FlynnMorgan Stanley100% hit rate on this stock · 17 targets measuredBuytarget $165Aug 20, 2026

Latest ratings

DateAnalystCallTarget
Sep 10, 2026Morten HerholdtHSBCBuyMaintained$175
Sep 7, 2026Courtney BreenBernsteinBuyMaintained$160
Aug 31, 2026Salim SyedMizuho SecuritiesBuyMaintained$170
Aug 28, 2026Gregory RenzaTruist FinancialBuyMaintained
Aug 27, 2026Evan SeigermanBMO CapitalBuyMaintained$174
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$120$130$140$150$160Oct 25 · Buy 21 · Hold 6 · Sell 0Oct 25Nov 25 · Buy 21 · Hold 6 · Sell 0Dec 25 · Buy 20 · Hold 6 · Sell 0Dec 25Jan 26 · Buy 22 · Hold 6 · Sell 0Feb 26 · Buy 20 · Hold 7 · Sell 0Feb 26Mar 26 · Buy 19 · Hold 7 · Sell 0Apr 26 · Buy 19 · Hold 6 · Sell 0Apr 26May 26 · Buy 20 · Hold 5 · Sell 0Jun 26 · Buy 20 · Hold 4 · Sell 0Jun 26Jul 26 · Buy 20 · Hold 5 · Sell 0Aug 26 · Buy 20 · Hold 4 · Sell 0Aug 26Sep 26 · Buy 20 · Hold 4 · Sell 0Oct 25 · avg. target $128Nov 25 · avg. target $131Dec 25 · avg. target $132Jan 26 · avg. target $136Feb 26 · avg. target $150Mar 26 · avg. target $155Apr 26 · avg. target $158May 26 · avg. target $158Jun 26 · avg. target $160Jul 26 · avg. target $159Aug 26 · avg. target $160Sep 26 · avg. target $161Oct 25 · month-end close $120Nov 25 · month-end close $126Dec 25 · month-end close $123Jan 26 · month-end close $142Feb 26 · month-end close $149Mar 26 · month-end close $139Apr 26 · month-end close $131May 26 · month-end close $134Jun 26 · month-end close $126Jul 26 · month-end close $130Aug 26 · month-end close $146Sep 26 · month-end close $145

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Sep 11, 2026 · 220 ratings

Frequently asked questions

Where can I trade GILD perpetual futures?

Gilead Sciences, Inc. (GILD) perpetual futures trade on 7 crypto venues, including BingX, HTX, Helix (Injective). PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade GILD around the clock?

Yes. Unlike the underlying stock, GILD perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on GILD perpetuals?

Right now the GILD perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to +5.5% across 7 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the GILD perp price compare to the Gilead Sciences, Inc. stock?

The venue-median GILD perp mark is $146.4 versus a reference stock price of $146.1, a basis of +0.2%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a GILD perpetual future?

A GILD perpetual is a derivative that tracks the price of Gilead Sciences, Inc. with no expiry date. It lets you take long or short exposure to Gilead Sciences, Inc. on crypto venues, around the clock.

What is GILDUSDT perpetual?

GILDUSDT is the symbol most crypto exchanges use for the Gilead Sciences, Inc. perpetual settled in USDT (Tether). It tracks the GILD share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

GILD perpetuals · perpequities.comGILD perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/gild-perp"><img src="https://perpequities.com/badge/gild-perp.svg" width="240" height="64" alt="GILD perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of GILD perps

Weekly digest by email

The listings, funding and moves that matter for GILD — one email every Sunday.

Watchlist and alerts

Price and funding alerts for GILD, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X